These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37953569)

  • 1. An integrated model of CDCA5 and FOXM1 expression combined with a residual disease that predicts prognosis in ovarian cancer patients.
    Zhang Q; Zhang R; Liu M; Wu H; Yang B
    Cell Mol Biol (Noisy-le-grand); 2023 Oct; 69(10):143-149. PubMed ID: 37953569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDCA5 accelerates progression of breast cancer by promoting the binding of E2F1 and FOXM1.
    Xiong Y; Shi L; Li L; Yang W; Zhang H; Zhao X; Shen N
    J Transl Med; 2024 Jul; 22(1):639. PubMed ID: 38978058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of
    Bai L; Ren Y; Cui T
    J Comput Biol; 2020 Jun; 27(6):965-974. PubMed ID: 31593490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of FOXM1 predicts poor prognosis and promotes cancer cell proliferation, migration and invasion in epithelial ovarian cancer.
    Wen N; Wang Y; Wen L; Zhao SH; Ai ZH; Wang Y; Wu B; Lu HX; Yang H; Liu WC; Li Y
    J Transl Med; 2014 May; 12():134. PubMed ID: 24885308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.
    Zhao F; Siu MK; Jiang L; Tam KF; Ngan HY; Le XF; Wong OG; Wong ES; Gomes AR; Bella L; Khongkow P; Lam EW; Cheung AN
    PLoS One; 2014; 9(11):e113478. PubMed ID: 25411964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRIM24 aggravates the progression of ovarian cancer through negatively regulating FOXM1 level.
    Zhou HE; Pan SS; Han H
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10647-10656. PubMed ID: 31858531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical significance of FOXM1 and Gli-1 protein expression in high-grade ovarian serous carcinoma].
    Zhang J; Li ZY; Duan XJ; Fan XM; Liu WN; Li YH
    Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):904-908. PubMed ID: 27998466
    [No Abstract]   [Full Text] [Related]  

  • 9. FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.
    Breyer J; Wirtz RM; Erben P; Rinaldetti S; Worst TS; Stoehr R; Eckstein M; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W
    BJU Int; 2019 Jan; 123(1):187-196. PubMed ID: 30120861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDCA5 promoted cell invasion and migration by activating TGF-β1 pathway in human ovarian cancer cells.
    Zhang Q; Zhang R; Li Y; Yang X
    J Ovarian Res; 2024 Mar; 17(1):68. PubMed ID: 38539247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDCA5 is negatively regulated by miR-326 and boosts ovarian cancer progression.
    Gao A; Hu Y; Zhu W
    J BUON; 2021; 26(2):544-552. PubMed ID: 34077004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forkhead box M1 (FOXM1) expression predicts disease free survival and may mediate resistance to chemotherapy and hormonotherapy in male breast cancer.
    Abdeljaoued S; Bettaieb L; Nasri M; Adouni O; Goucha A; Bouzaiene H; Boussen H; Rahal K; Gamoudi A
    Breast Dis; 2018; 37(3):109-114. PubMed ID: 29504520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
    Wang Y; Wen L; Zhao SH; Ai ZH; Guo JZ; Liu WC
    Lung Cancer; 2013 Feb; 79(2):173-9. PubMed ID: 23177020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes.
    Rinaldetti S; Wirtz RM; Worst TS; Eckstein M; Weiss CA; Breyer J; Otto W; Bolenz C; Hartmann A; Erben P
    Oncotarget; 2017 Jul; 8(29):47595-47606. PubMed ID: 28498805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma.
    Hou S; Chen X; Li M; Huang X; Liao H; Tian B
    Aging (Albany NY); 2020 Jul; 12(14):14542-14555. PubMed ID: 32694239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC).
    Tian Y; Wu J; Chagas C; Du Y; Lyu H; He Y; Qi S; Peng Y; Hu J
    BMC Cancer; 2018 Nov; 18(1):1187. PubMed ID: 30497429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of FOXM1 in solid tumors: a systematic review and meta-analysis.
    Li L; Wu D; Yu Q; Li L; Wu P
    Oncotarget; 2017 May; 8(19):32298-32308. PubMed ID: 28427178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated clinical characteristics and omics analysis identifies a ferroptosis and iron-metabolism-related lncRNA signature for predicting prognosis and therapeutic responses in ovarian cancer.
    Feng S; Yin H; Zhang K; Shan M; Ji X; Luo S; Shen Y
    J Ovarian Res; 2022 Jan; 15(1):10. PubMed ID: 35057848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From imaging to clinical outcome: dual-region CT radiomics predicting FOXM1 expression and prognosis in hepatocellular carcinoma.
    Chen X; Tang Y; Wu D; Li R; Lin Z; Zhou X; Wang H; Zhai H; Xu J; Shi X; Zhang G
    Front Oncol; 2023; 13():1278467. PubMed ID: 37817774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
    Li W; Huang L; Qi N; Zhang Q; Qin Z
    BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.